FDA advisers endorse Moderna's mRNA flu vaccine
The FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously on June 18 that the benefits of Moderna’s seasonal mRNA influenza vaccine outweigh its risks across the age groups studied, STAT News reports . The endorsement covers a shot that had become a target of broader political scrutiny of mRNA technology.
Advisory committee votes are not binding, but they typically guide the FDA’s licensing decisions and shape how a product is positioned in the market. A favorable vote here matters because it would make an mRNA flu vaccine available alongside conventional egg- and cell-based shots, and because the technology has faced resistance within the current administration’s health leadership — leaving the agency’s final call as the decision to watch.